ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Galecto Inc

Galecto Inc (GLTO)

3.50
-0.0535
(-1.51%)
3.50
0.00
(0.00%)

Galecto Inc (GLTO) Quote

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
3.50
( -1.51% )
Bid
3.50
Ask
3.67
Volume
31,095
3.50 Day's Range 3.96
2.01 52 Week Range 15.50
Market Cap
Previous Close
3.5535
Open
3.75
Last Trade
1
@
3.7
Last Trade Time
Financial Volume
$ 115,271
VWAP
3.7071
Average Volume (3m)
46,060
Shares Outstanding
1,322,359
Dividend Yield
-
PE Ratio
-0.22
Earnings Per Share (EPS)
-16.21
Revenue
-
Net Profit
-21.44M

About Galecto Inc

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitor... Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Galecto Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GLTO. The last closing price for Galecto was $3.55. Over the last year, Galecto shares have traded in a share price range of $ 2.01 to $ 15.50.

Galecto currently has 1,322,359 shares outstanding. The market capitalization of Galecto is $4.70 million. Galecto has a price to earnings ratio (PE ratio) of -0.22.

GLTO Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.051.449275362323.454.09993.264423413.70216068CS
40.299.034267912773.214.09993.0684222213.54518516CS
120.8532.07547169812.654.09992.59460603.03112438CS
26-1.26-26.47058823534.767.32.011481075.47366316CS
52-11.25-76.271186440714.7515.52.011291028.32967382CS
156-43-92.473118279646.592.52.0119112422.16934578CS
260-390.75-99.1122384274394.25449.752.0121556270.47254921CS

GLTO - Frequently Asked Questions (FAQ)

What is the current Galecto share price?
The current share price of Galecto is $ 3.50
How many Galecto shares are in issue?
Galecto has 1,322,359 shares in issue
What is the market cap of Galecto?
The market capitalisation of Galecto is USD 4.7M
What is the 1 year trading range for Galecto share price?
Galecto has traded in the range of $ 2.01 to $ 15.50 during the past year
What is the PE ratio of Galecto?
The price to earnings ratio of Galecto is -0.22
What is the reporting currency for Galecto?
Galecto reports financial results in USD
What is the latest annual profit for Galecto?
The latest annual profit of Galecto is USD -21.44M
What is the registered address of Galecto?
The registered address for Galecto is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Galecto website address?
The website address for Galecto is www.galecto.com
Which industry sector does Galecto operate in?
Galecto operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
YHCLQR House Inc
$ 10.76
(172.41%)
49.7M
NUWENewellis Inc
$ 15.94
(131.18%)
40.03M
APMAptorum Group Ltd
$ 1.93
(99.01%)
196.41M
RGTXDefiance Daily Target 2X Long RGTI ETF
$ 56.25
(60.49%)
3.24M
DTSTData Storage Corporation
$ 5.2952
(56.66%)
14.95M
ZVSAZyVersa Therapeutics Inc
$ 0.31
(-43.53%)
12.45M
CGBSCrown LNG Holdings Ltd
$ 0.03795
(-38.09%)
197.49M
CYCCCyclacel Pharmaceuticals Inc
$ 8.16
(-33.82%)
3.55M
NCPLNetcapital Inc
$ 3.2519
(-28.53%)
2.22M
JUNSJupiter Neurosciences Inc
$ 2.125
(-28.45%)
929.83k
GTIGraphjet Technology
$ 0.102
(39.73%)
452.35M
OPENOpendoor Technologies Inc
$ 1.49
(43.27%)
303.74M
IXHLIncannex Healthcare Ltd
$ 0.3869
(13.79%)
284.9M
CGBSCrown LNG Holdings Ltd
$ 0.03795
(-38.09%)
197.47M
APMAptorum Group Ltd
$ 1.93
(99.01%)
196.41M

GLTO Discussion

View Posts
Monksdream Monksdream 2 months ago
GLTO, 10Q due Monday 5/5
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
GLTO 10Q due Monday 4/28
πŸ‘οΈ0
swingforthe fence swingforthe fence 4 months ago
Got in at $5.21 Friday
πŸ‘οΈ0
swingforthe fence swingforthe fence 4 months ago
Let Go Get It GLTO
πŸ‘οΈ0
Mr. Zen Mr. Zen 4 months ago
Is this still accurate?, if it is you have a time bomb on your hands. Easy double would just be a start.

Outstanding Shares
1,316,989
10/30/2024
πŸ‘οΈ0
Retire43 Retire43 9 months ago
GALT MENTIONED IN THIS ARTICLE.

https://www.zerohedge.com/news/2024-10-15/what-merck-doesnt-want-you-know-about-keytruda
πŸ‘οΈ0
Retire43 Retire43 9 months ago
Please watch this and comment your opinion

πŸ‘οΈ0
Monksdream Monksdream 10 months ago
GLTO under $15
πŸ‘οΈ0
Retire43 Retire43 1 year ago
BIXT:

https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html
πŸ‘οΈ0
Retire43 Retire43 1 year ago
Share this.


https://medicaldialogues.in/medicine/news/galectin-3-promising-biomarker-for-predicting-long-covid-among-patients-of-covid-19-study-129158
πŸ‘οΈ0
Retire43 Retire43 1 year ago
Share this news with everyone, you know

https://www.insiderfinancial.com/post/playing-the-bird-flu-trade-cvac-bixt-nnvc-govx-dyai-nvax
πŸ‘οΈ0
Retire43 Retire43 1 year ago
Todays emerging growth conference
CEO DAVID PLATT $BIXT
BioxyTran.

https://emerginggrowth.com/emerging-growth-conference-70/

πŸ‘οΈ0
Retire43 Retire43 1 year ago
https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22
πŸ‘οΈ0
Retire43 Retire43 2 years ago
https://www.zerohedge.com/news/2023-12-12/disease-x-resistance-futile
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 2 years ago
glto on the move
πŸ‘οΈ0
subslover subslover 2 years ago
Galecto Announces Plans to Explore Strategic Alternatives
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Galecto has made the determination to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.

As part of this evaluation process, Galecto will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, divestiture of its assets, technologies or capabilities, or other transaction. There can be no assurance that its exploration will result in Galecto pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all.

In connection with the evaluation of strategic alternatives, Galecto plans to implement a restructuring plan that includes reducing its workforce by approximately 29 people, or approximately 70% of its existing headcount.

Galecto has not set a timetable for completion of the evaluation process and does not intend to disclose further developments or guidance on the status of its programs unless and until it is determined that further disclosure is appropriate or necessary.

As of June 30, 2023, Galecto’s cash, cash equivalents and investments balance was $52.1 million.
πŸ‘οΈ0
Retire43 Retire43 2 years ago
Please share this!

Science buff #Investor #vaccinated #unvaccinated #COVID19 #LongCovid #Covid #masks #masksdontwork we want all to hear about a new paradigm in #drug development. $BIXT @buffalofireside talk about #galectin #drugs & potent #antiviral https://t.co/vma2hIy6CY @EnemyInAState pic.twitter.com/ARIwmsS65t— Mike Sheikh (@MikeSheikh2) September 20, 2023
πŸ‘οΈ0
Retire43 Retire43 2 years ago
Look at this Reprint. Share this !

https://www.preprints.org/manuscript/202309.0077/v1
πŸ‘οΈ0
Retire43 Retire43 2 years ago
https://www.zerohedge.com/news/2023-09-12/mask-mandates-unpopular-due-existence-next-gen-antivirals-pipeline
πŸ‘οΈ0
Retire43 Retire43 2 years ago
Did anyone catch this today ?

H.C. Wainwright 25th Annual Global Investment Conference

Date: Monday, September 11, 2023
Time: 7:00 am ET
Location: New York City, NY
πŸ‘οΈ0
Butchmass Butchmass 2 years ago
When is this company going to start doing more to publicize itself. They could be more up front and active with the share holders.
πŸ‘οΈ0
Triple nickle Triple nickle 2 years ago
Added a few down here
πŸ‘οΈ0
Monksdream Monksdream 2 years ago
Damn shame
Sold quite a while ago at a profit
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
$GLTO (.80) -65% Galecto to discontinue development of lung disease treatment
Reuters
Tue, August 15, 2023 at 7:35 AM EDT

Aug 15 (Reuters) - Galecto Inc said on Tuesday it will dicontinue development of its lung disease treatment after it failed to meet its primary goal in a mid-stage study. (Reporting by Sriparna Roy in Bengaluru; Editing by Arun Koyyur)

https://finance.yahoo.com/news/galecto-discontinue-development-lung-disease-113556937.html
πŸ‘οΈ0
Monksdream Monksdream 2 years ago
GLTO now ;No 11; on the Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
Monksdream Monksdream 2 years ago
GLTO new 52/week high
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
Butchmass Butchmass 2 years ago
Monksdream, I hope we see considerable more traffic on this board soon. Earnings coming out 7/28/2023.
πŸ‘οΈ0
Monksdream Monksdream 2 years ago
GLTO No 3 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock